New medication combination triggers weight loss and good blood sugar control in people with type 2 diabetes
The combined effects of semaglutide with cagrilintide in people with type 2 diabetes results in significant weight loss and improvements in blood sugar control, new research shows.
An international team has found that treatment with cagrilintide (CagriSema) resulted in significantly greater weight loss than either semaglutide or CagriSema alone.
A mean reduction in bodyweight of 15.6 per cent in 32 weeks was seen in those given the new combination, CagriSema, compared to five per cent weight reduction in the same timeframe as those given semaglutide alone.
The trial took place across 17 sites in the USA in 2021. A total of 92 participants with type 2 diabetes, who had an average age of 58, were given either cagrilintide, semaglutide or the combined CagriSema once a week.
The participants’ HbA1c and bodyweight at the end of the trial were compared to their levels at the start.
The haemoglobin A1c (HbA1c) test measures the amount of blood sugar (glucose) attached to haemoglobin. Haemoglobin is the part of your red blood cells that carries oxygen from your lungs to the rest of your body. It is an important blood test that gives a good indication of how well diabetes is being controlled.
Professor of Diabetes Medicine, Melanie Davies, who is the Director of the National Institute for Health and Care Research (NIHR) Leicester Biomedical Research Centre (BRC) and NIHR Patient Recruitment Centre, Leicester, said: “We wanted to better understand the impact of combining semaglutide with CagriSema on blood sugar control and weight loss in patients with type 2 diabetes, and so compared the effects to semaglutide and CagriSema alone.
“We were very pleased to see that, in people with type 2 diabetes, treatment with CagriSema resulted in clinically relevant improvements in blood sugar levels control. And, excitingly we saw that treatment with this new combination.”
She added: “CagriSema also resulted in significantly greater weight loss compared to either semaglutide or CagriSema alone, and was well tolerated by participants in the study.
“This supports further investigation of CagriSema in longer and larger phase 3 studies and in more diverse populations, which are open and recruiting participants in Leicester.”
The phase 3 trials are investigating the efficacy and safety of CagriSema in participants with type 2 diabetes who are overweight or living with obesity (BMI over 27), and the cardiovascular safety in participants with obesity (BMI over 30) and established cardiovascular disease.
These studies are being delivered in the five NIHR Patient Recruitment Centres (PRCs) located throughout England.
Further information is available on the following website: www.redefine3.org.uk
The paper ‘Efficacy and safety of co-administered once-weekly cagrilintide 2•4 mg with once-weekly semaglutide 2•4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial’ was published in The Lancet on 23 June 2023.